Sandali Seneviratne

Sandali Seneviratne

Auto-generated profile, based on publicly available information

Sandali Seneviratne

Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University. Canberra, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SSSrinivasan Sundararaj
Srinivasan Sundararaj
SSSandali Seneviratne
Sandali Seneviratne
SWSimon J Williams
Simon J Williams
AEAnselm Enders
Anselm Enders
MCMarco G. Casarotto
Marco G. Casarotto
Interferon regulatory factor 4 (IRF4) is a key transcription factor (TF) in the regulation of immune cells, including B and T cells. It acts by binding DNA as both a homodimer and, in conjunction with other TFs, as a heterodimer. The choice of homo and heterodimeric/ DNA interactions is a critical aspect in the control of the transcriptional program and cell fate outcome. To characterize the nature of this interaction in the homodimeric complex, we have determined the crystal structure of the IRF4/ISRE homodimeric complex. We show that the complex formation is aided by a substantial DNA deformation with co-operative binding achieved exclusively through protein–DNA contact. This markedly contrasts with the heterodimeric form where DNA bound IRF4 is shown to physically interact with PU.1 TF to engage EICE1. We also show that the hotspot residues (Arg98, Cys99 and Asn102) contact both consensus and non-consensus sequences with the L1 loop exhibiting marked flexibility. Additionally, we identified that IRF4L116R, a mutant associated with chronic lymphocytic leukemia, binds more robustly to DNA thereby providing a rationale for the observed gain of function. Together, we demonstrate key structural differences between IRF4 homo and heterodimeric complexes, thereby providing molecular insights into IRF4-mediated transcriptional regulation.

8 December 2023 in Science Advances
Verified
Journal Article
Open access
CTCynthia Turnbull
Cynthia Turnbull
JBJosiah Bones
Josiah Bones
MSMaurice Stanley
Maurice Stanley
AMArti Medhavy
Arti Medhavy
HWHao Wang
Hao Wang
CVCarola G. Vinuesa
Carola G. Vinuesa
Autosomal dominant loss-of-function (LoF) variants in cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ) cause immune dysregulation with autoimmunity, immunodeficiency and lymphoproliferation (IDAIL). Incomplete penetrance and variable expressivity are characteristic of IDAIL caused by CTLA-4 haploinsufficiency (CTLA-4h), pointing to a role for genetic modifiers. Here, we describe an IDAIL proband carrying a maternally inherited pathogenic CTLA4 variant and a paternally inherited rare LoF missense variant in CLEC7A, which encodes for the β-glucan pattern recognition receptor DECTIN-1. The CLEC7A variant led to a loss of DECTIN-1 dimerization and surface expression. Notably, DECTIN-1 stimulation promoted human and mouse regulatory T cell (T reg ) differentiation from naïve αβ and γδ T cells, even in the absence of transforming growth factor–β. Consistent with DECTIN-1’s T reg -boosting ability, partial DECTIN-1 deficiency exacerbated the T reg defect conferred by CTL4-4h. DECTIN-1/ CLEC7A emerges as a modifier gene in CTLA-4h, increasing expressivity of CTLA4 variants and acting in functional epistasis with CTLA-4 to maintain immune homeostasis and tolerance.

16 December 2021 in Protein Science
Verified
Journal Article
Closed access
PDF file
SSSrinivasan Sundararaj
Srinivasan Sundararaj
SSSandali Seneviratne
Sandali Seneviratne
SWSimon J Williams
Simon J Williams
AEAnselm Enders
Anselm Enders
MCMarco G. Casarotto
Marco G. Casarotto

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RJRebecca A. Jaeger
Rebecca A. Jaeger
NRNadia A. Roberts
Nadia A. Roberts
CTCynthia M. Turnbull
Cynthia M. Turnbull
SSSandali Seneviratne
Sandali Seneviratne
RBRebecca L. Buckland
Rebecca L. Buckland
AEAnselm Enders
Anselm Enders
The decision of naïve T cells to differentiate into a specific Th cell subset after antigen encounter is a critical pivot point of the immune response and, when out of balance, can lead to autoimmunity, allergy or immunodeficiency. Th subset differentiation is determined by the expression of transcription factors including IRF4. We here describe a point mutation (IRF4 L116R ) in the DNA-binding domain of IRF4 leading to a dysregulation of CD4-T cell subsets and their functions. This point mutation does not alter overall protein expression. In sharp contrast to IRF4-null mice, neither the CD4/CD8 ratio nor T cell activation and memory is altered in naïve mice carrying the point mutation. However, IRF4 L116R T cells are reduced in their capability to differentiate into Th1, Th17 and Treg cells in a dose-dependent manner, contrasting with the findings in IRF4 KO T cells. Particularly striking is the loss of Th1-differentiation in T cells from homozygous I rf4 L116R/L116R mice while T cells completely lacking IRF4 show no reduction in Th1 differentiation. Furthermore, despite maintained ability to generate Th17 cells, expression of the IRF4 L116R variant protects mice against disease development in the Th17 cell-dependent EAE mouse model of neuroinflammation. This contrasts with IRF4 knock-out mice, where expression of one wild-type allele of IRF4 is sufficient for full disease development. Together our results show that the L116R point mutation in IRF4 can selectively alter the differentiation and function of some CD4 T cell subsets and suggest that the L116R mutation is not a classical loss- or gain-of-function variant.